Explore

Trendline Trendline
STORM Therapeutics Secures $56M for RNA-Targeting Cancer Drug Trials

STORM Therapeutics Secures $56M for RNA-Targeting Cancer Drug Trials

STORM Therapeutics Secures $56M for RNA-Targeting Cancer Drug Trials
Trendline Trendline
Parabilis Medicines Appoints New Executives to Drive Growth and Innovation

Parabilis Medicines Appoints New Executives to Drive Growth and Innovation

Parabilis Medicines Appoints New Executives to Drive Growth and Innovation
Trendline Trendline
Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations, Enhancing U.S. Presence

Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations, Enhancing U.S. Presence

Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations, Enhancing U.S. Presence
Trendline Trendline
Greywolf Therapeutics Appoints Edwin Moses as Chair Amid Promising Oncology Developments

Greywolf Therapeutics Appoints Edwin Moses as Chair Amid Promising Oncology Developments

Greywolf Therapeutics Appoints Edwin Moses as Chair Amid Promising Oncology Developments
Trendline Trendline
Kivu Bioscience Names Mohit Trikha as CEO to Drive Oncology Innovations

Kivu Bioscience Names Mohit Trikha as CEO to Drive Oncology Innovations

Kivu Bioscience Names Mohit Trikha as CEO to Drive Oncology Innovations
Trendline Trendline
Kivu Bioscience Appoints Mohit Trikha as CEO to Drive Oncology Advancements

Kivu Bioscience Appoints Mohit Trikha as CEO to Drive Oncology Advancements

Kivu Bioscience Appoints Mohit Trikha as CEO to Drive Oncology Advancements
Trendline Trendline
FDA Grants Fast Track Designation to Opna Bio's OPN-6602 for Multiple Myeloma Treatment

FDA Grants Fast Track Designation to Opna Bio's OPN-6602 for Multiple Myeloma Treatment

FDA Grants Fast Track Designation to Opna Bio's OPN-6602 for Multiple Myeloma Treatment
Trendline Trendline
Parabilis Medicines Strengthens Leadership with Key Appointments to Drive Growth

Parabilis Medicines Strengthens Leadership with Key Appointments to Drive Growth

Parabilis Medicines Strengthens Leadership with Key Appointments to Drive Growth
Trendline Trendline
Adcendo ApS Secures $75 Million Series C Financing to Advance ADC Cancer Therapies

Adcendo ApS Secures $75 Million Series C Financing to Advance ADC Cancer Therapies

Adcendo ApS Secures $75 Million Series C Financing to Advance ADC Cancer Therapies
Trendline Trendline
Iterion Therapeutics Presents New Data on Tegavivint for Wnt-Driven Cancers at AACR Meeting

Iterion Therapeutics Presents New Data on Tegavivint for Wnt-Driven Cancers at AACR Meeting

Iterion Therapeutics Presents New Data on Tegavivint for Wnt-Driven Cancers at AACR Meeting
Trendline Trendline
Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment

Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment

Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment
Trendline Trendline
San Diego Startup Neomorph Secures $100M for Cancer Drug Development

San Diego Startup Neomorph Secures $100M for Cancer Drug Development

San Diego Startup Neomorph Secures $100M for Cancer Drug Development